Row escalates at Trinity Biotech

A group of shareholders owning 10 per cent of Nasdaq listed Bray medical firm Trinity Biotech has warned it will take its case to the Office of the Director of Corporate Enforcement (ODCE) in a row over its attempts to requisition a shareholder meeti

21st February, 2009

A group of shareholders owning 10 per cent of Nasdaq listed Bray medical firm Trinity Biotech has warned it will take its case to the Office of the Director of Corporate Enforcement (ODCE) in a row over its attempts to requisition a shareholder meeting and oust the company’s board.

The shareholder group, headed by Kansas-based investor Tom Reidy, a former executive in a Trinity subsidiary, said it was considering making a formal complaint to...

Subscribe from just €1 for the first month!

Currency

What's Included

With any subscription you will have access to

  • 971569B3-2C5E-4C45-B798-CEADE16987A8

    Unlimited multi-device access to our iPad, iPhone and Android Apps

  • 099C8662-C57C-42F2-9426-F2F90DF17C8F

    Unlimited access to our eReader library

  • 198AE43B-B9CF-4892-8769-D63C2104BA08

    Exclusive daily insight and opinion seven days a week

  • D8F37B78-25E4-4E4A-A376-4F5789B1564A

    Create alerts to never miss a subject that matters to you

  • B15F2521-37CD-4E02-B898-730A20D39F7F

    Get access to exclusive offers for subscribers on gifts and experiences

  • A564FE02-1AB8-4579-AF9D-BA32A2E5ACA7

    Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine

Share this post

Related Stories

The year in review

Newsround: What Thursday’s papers say